Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. [PDF]
Antimicrob Agents ChemotherAvery LM +5 more
europepmc +1 more source
Structural insights into the activity of carbapenemases: understanding the mechanism of action of current inhibitors and informing the design of new carbapenem adjuvants. [PDF]
RSC Med ChemHatzisarantinos T +5 more
europepmc +1 more source
Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. [PDF]
Microbiol SpectrKim TY +7 more
europepmc +1 more source
<i>Acinetobacter towneri</i> harbouring <i>bla</i> <sub>NDM-1</sub> and <i>bla</i> <sub>OXA-58</sub>: genomic characterization of the first human isolate from Brazil. [PDF]
New Microbes New InfectRodrigues DCS +6 more
europepmc +1 more source
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). [PDF]
J Antimicrob ChemotherSader HS +4 more
europepmc +1 more source
Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies. [PDF]
Diagnostics (Basel)Morena R +3 more
europepmc +1 more source
Cefepime failure for the treatment of cefepime-susceptible, KPC-producing <i>Escherichia coli</i> emphysematous cystitis. [PDF]
ASM Case RepMorelan J +3 more
europepmc +1 more source
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis. [PDF]
Ther Drug MonitGatti M +6 more
europepmc +1 more source